Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complement inhibition with C1 esterase inhibitor after aneurysmal subarachnoid hemorrhage
2025-520540-15-00Phase 2Authorised
- Sponsor
- Haaglanden Medical Centre
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of c1-esterase inhibitor in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Haaglanden Medical Centre. Primary endpoints: Delayed cerebral ischemia incidence and Complications during hospitalization. Planned start Jan 2025; status: authorised.
02
Drugs
c1-esterase inhibitor
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2025-520540-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520540-15-00.